Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Status:
Recruiting
Trial end date:
2027-10-30
Target enrollment:
Participant gender:
Summary
The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide
prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given
as a first line treatment compared to treatment with high dose (60 mg) long-acting
octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients
previously treated with SSAs in the absence of progression.